Trial Profile
An open-label, single-center and single-arm clinical study for sequential infusion of anti-CD22 and anti-CD19 CAR-T cells for patients with relapsed or refractory B-cell malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Anti-CD19-chimeric-antigen-receptor-T-cell-therapies-Wuhan-Bio-Raid-Biotechnology (Primary) ; Anti-CD22-chimeric-antigen-receptor-T-cell-therapies-Wuhan-Bio-Raid-Biotechnology (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 13 Dec 2022 Results (n=61; between January 2017 and May 2022) exploring the potentially effective salvage strategies and finally improving the prognosis of them by analyzing the efficacy and safety especially between the second time CTI (CTI2) and other different therapies (non-CTI2), presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 01 Aug 2021 Results of a subgroup analysis assessing the evaluate the efficacy and safety of CAR19/22 T cell therapy in six refractory Burkitt's lymphoma cases with poor genetic prognostic factors published in the Cancer Immunology Immunotherapy